ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Brings back memories

<< Previous

Bullboard Posts

Next >>

Post by retiredcopon Apr 25, 2023 3:04pm

265 Views

Post# 35413028

Brings back memories

FDA gives fast track approval for Biogen's ALS treatment. Not sure if anyone's remember but around 2008-2009 Biogen gave AMF A few million to licence out our sod1 science for ALS. Biogen didn't do anything with the science and eventually AMF just did not renew the licencing agreement . Again PMN will benefit from this FDA approval... one of our ALS treatment being developed is also based on sod1 so we now have something to compare with...win win situation

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China